Echinacea for the Common Cold?

A meta-analysis published in Pharmacotherapy (2000;20(6):690–697) reviewed the evidence for Echinacea in the prevention and treatment of upper respiratory tract infections. The reviewers evaluated studies identified through the MEDLINE database and were generally critical of study design and methodology, noting that most trials had identifiable limitations. Despite these concerns, the authors concluded that some evidence exists to support a potential role for Echinacea in upper respiratory infections.

Several individual studies illustrate both the promise and the limitations of the research.

One randomized, double-blind, placebo-controlled trial published in European Journal of Clinical Research (1997;9:261–269) evaluated a commercial preparation of Echinacea purpurea (Echinagard). The study included 120 subjects with acute upper respiratory tract infections, with 60 assigned to the treatment group and 60 to placebo.

Participants in the treatment group received 20 drops of E. purpurea in four ounces of water every two hours on the first day, followed by the same dose three times daily for the next nine days. Symptoms were recorded using daily questionnaires at baseline and on day 10. Only 40% of the Echinacea group developed fully expressed cold symptoms, compared with 60% of the placebo group. The authors concluded that Echinacea initiated at the earliest signs of infection appeared to inhibit progression and shorten symptom duration.

Reviewers of the meta-analysis noted limitations in this study, including reliance on subjective symptom questionnaires, lack of physician examination until after symptom resolution, and unclear dosing details.

A second study reviewed used Echinacea pallida root extract and was published in Complementary Therapies in Medicine (1997;5:40–42). In this trial, 160 subjects with colds lasting fewer than three days received either 900 mg/day of liquid E. pallida extract or placebo. Participants were evaluated by a physician at baseline, at days 3–4, and again at days 8–10.

Investigators distinguished viral from bacterial infections using white blood cell counts, with elevated lymphocytes suggesting viral infection and elevated neutrophils suggesting bacterial infection. Subjects receiving E. pallida experienced shorter illness duration in both bacterial infections (9.8 vs. 13 days) and viral infections (9.1 vs. 13 days), along with reduced symptom severity.

Although the studies reviewed varied in quality and design, the authors of the meta-analysis concluded that Echinacea shows potential benefit for upper respiratory tract infections, particularly when used early in the course of illness. This observation aligns with clinical experience in natural healthcare, where Echinacea is commonly used at the first signs of a cold rather than after symptoms are fully established.